摘要
目的了解表达SP100抗体的原发性胆汁性肝硬化（PBC）患者的临床特点，为临床上诊断和随访PBC患者提供依据。方法回顾陛分析70例PBC患者，分为抗SP100阳性组12例、抗SP100阴性组58例，比较其症状、肝功能、免疫学指标及肝病理组织学等特征。用SPSS11．5统计软，两组间均数比较采用成组资料f检验，非正态资料采用秩和检验，等级资料采用Ridit分析。结果抗SP100阳性组和抗SP100阴性组，在年龄、性别、临床表现、抗线粒体抗体M2亚型（AMA-M2）表达，差异均无统计学意义。碱性磷酸酶、Y-谷氨酰转肽酶中位数和IgM平均值抗SP100阳性组分别为466U／L、728U／L和（4．25±2．86）g／L，抗SP100阴性组分别为163U／L、154U／L和（2．81±2．15）g／L，抗SP100阳性组碱性磷酸酶、Y-谷氨酰转肽酶和IgM水平均高于抗SP100阴性组，Z值分别为3．71和3．38、f=2．06，P值均〈0．05，差异有统计学：意义。40例AMA-M2阴性的PBC患者中抗核抗体阳性18例，占45％，抗SP100阳性8例，占2％，AMA-M2阴性的PBC患者中抗核抗体阳性率高于抗SP100阳性率，P=0．021。AMA-M2表达在抗SPl00阳性组和抗SP100阴性组间差异无统计学意义。病理组织学上，PBC各期患者均有SP100抗体表达。结论表达SP100抗体的PBC患者的临床特征类似于未表达SP100抗体者，对SP100抗体表达的PBC患者更应重视随访。
Objeclive To evaluate the clinical features of patients with primary biliary cirrhosis （PBC） and positive expression of SP100 autoantibody in order to generate a clinical screening profile that may help to increase early diagnosis and timely initiation of therapy. Methods The clinical data of 70 patients who were diagnosed with PBC by liver biopsy between January 2006 to December 2009 at the Second Affiliated Hospital of Kunming Medical University of Hepatobiliary and Pancreatic Medicine were retrospectively collected for analysis. The patients were divided according to expression of anti-SP100： positive patients, n = 12; negative patients, n = 58. The groups were comparatively analyzed for differences in clinical, biochemical, immunological, and histopathological parameters. Normally dislributed data was compared by t-test, and non- normally data was compared by rank-sum test. Results There was no significant difference in age among the SP100-positive and SP100-negative patients （51.6 ± 9.5 vs. 50.0 ± 14.7 years, P 〉 0.05）. The SP100-positive group had significantly more women （80.0% vs. 61.9%, X2 = 0.32, P 〉 0.05） and more patients with atypical symptoms （18.2% vs. 13.8%） but the difference of the latter did not reach statistical significance. The SP100- positive group had significantly higher levels of alkaline phosphatase （ALP; 466 vs. 163 U/L, Z = 3.71 ）, gamma-glutamyl-lranspepfidase （GGT; 728 vs. 154 U/L,Z= 3.38）, and immunoglobulin M （IgM; 4.25 q- 2.86 vs. 2.81 q- 2.15, t = 2.06, P 〈 0.05）. Forty of the total patients tested negative for antimitochondrial （AMA）-M2 antibodies, and eight of those were SP100-positive （20.0%） while 18 were antinuclear （ANA） antibody-positive （45.0%）. There were significantly more AMA-M2-negative/ANA-positive patients than SP 100-positive patients （P = 0.021）. Anti-SP 100 expression was not associated with the pathological stage of PBC （R1 = 5.500, P 〉 0.05）. Conclusion SP100- positive PBC may show a bias towards
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2013年第5期359-362,共4页
Chinese Journal of Hepatology
基金
云南省自然科学基金[2010CDl70],云南省科技计划及国际合作项目[2006GHl4]
关键词
肝硬化
胆汁性
诊断
临床研究
抗体
SP100
Liver cirrhosis, biliary
Diagnosis
Clinical research
Antibodies
SPIO0
